Bristol-Myers Squibb (BMY), Pfizer (PFE) Will Present New Eliquis Data at ESC Congress 2016

August 23, 2016 7:00 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at ESC Congress 2016, to be held August 27–31 in Rome, Italy. These new data from post-hoc analyses from ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation) and retrospective real-world data analyses continue to underscore the Alliance’s commitment to the evaluation of Eliquis for patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE). Of note, several of the real-world data analyses are part of ACROPOLIS™ (Apixaban ExperienCe Through Real-WOrld POpuLatIon Studies), a global real-world data research program designed to further evaluate the effectiveness and safety of apixaban in routine clinical practice.

“The Bristol-Myers Squibb and Pfizer Alliance is pleased to share 19 abstracts, which include new real-world analyses, as well as new sub-analyses from the pivotal Phase 3 ARISTOTLE trial,” said Rory O’Connor, M.D., Chief Medical Officer, Internal Medicine, Pfizer Innovative Health. “We look forward to the opportunity to contribute to the scientific discussion and continued research during ESC Congress 2016.”

“As patient and provider needs continue to evolve, it’s essential that we deepen our understanding of how medicines are working in real-world situations,” said Jack Lawrence, M.D., Vice President, Cardiovascular Specialty Development, Bristol-Myers Squibb. “This year at ESC Congress 2016, we’ll be discussing new NVAF and VTE data that complement our robust body of clinical trial data.”

The complete list of Bristol-Myers Squibb and Pfizer Alliance presentations is included below. Abstracts can be accessed on the ESC Congress 2016 website.

Title Presenting Author/TypeDate/Time (BST)Location/Session
Phase 3 Clinical Trial Sub-Analyses

Patients with Atrial Fibrillation and History of Falls Are at High Risk for Bleeding but Have Less Bleeding with Apixaban than Warfarin: Results from the ARISTOTLE Trial

Session: New Trends in Antithrombotic Therapy for Atrial Fibrillation

Rao et al. /Oral, Rapid Fire

Aug. 28,11:10

Agora 1 – Poster Area

Efficacy and Safety of Apixaban versus Warfarin in Patients with Atrial Fibrillation and Active Cancer: Insights from the ARISTOTLE Trial

Session: New Trends in Antithrombotic Therapy for Atrial Fibrillation

Melloni et al. /Oral, Rapid Fire

Aug. 28,11:20

Agora 1 – Poster Area

Patients with Atrial Fibrillation Treated with Apixaban Are Less Likely to Discontinue Study Drug When Compared with Warfarin: Insights from the ARISTOTLE Trial

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation III

Xavier et al. /Poster

Aug. 28,14:00

Poster Area
Real-World Data and Other Analyses

Contemporary Results from EHR Study of Real-World Bleeding Risk among Elderly and Overall Non-Valvular Atrial Fibrillation Patients Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin

Session: New Trends in Antithrombotic Therapy for Atrial Fibrillation

Horblyuk et al. /Oral, Rapid Fire

Aug. 28,12:00

Agora 1 – Poster Area

Real-World Comparisons of Major Bleeding Risk and Major Bleeding-Related Hospitalization Costs among Elderly Non-Valvular Atrial Fibrillation Patients Newly Initiated on Apixaban or Warfarin

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation

Lip et al. /

Poster

Aug. 28,14:00

Poster Area

Is Major Bleeding Risk for Oral Anticoagulants Similar Between Non-Valvular Atrial Fibrillation Patients Newly Initiated on Warfarin and Propensity-Score Matched NOAC Initiators? A Real World Study

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation

Lip et al. /Poster

Aug. 28,14:00

Poster Area

Major Bleeding Risk in Patients 75 Years of Age or Older with Non-Valvular Atrial Fibrillation Initiating Oral Anticoagulants: A ‘Real-World’ Comparison of Warfarin, Apixaban, Dabigatran, or Rivaroxaban

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation II

Lip et al. /

Poster

Aug. 28,14:00

Poster Area

Is There a Difference in Treatment Persistence Across Oral Anticoagulants? Results of a UK Cohort Study Evaluating Oral Anticoagulation Therapy in an Atrial Fibrillation Population

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation

Stynes et al. /Poster

Aug. 28,14:00

Poster Area

Real-World Comparison of Major Bleeding and Associated Costs among Treatment-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban or Warfarin

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation II

Trocio et al. /Poster

Aug. 28,14:00

Poster Area

Aspirin, not without Bleeding Risk in the Real World: Results of a UK Cohort Study Evaluating the Use of Antiplatelet Therapy for Stroke Prevention in Atrial Fibrillation (AF)

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation III

Ridha et al. / Poster

Aug. 28,14:00

Poster Area

Is Aspirin Monotherapy Effective for Stroke Prevention in the Real World? A UK Cohort Study Evaluating the Incidence of Stroke in the Absence of Anticoagulation in Atrial Fibrillation (AF)

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation II

Ridha et al. /

Poster

Aug. 28,14:00

Poster Area
Differences in the Characteristics of Patients with Non-Valvular Atrial Fibrillation Who Are Newly Prescribed Apixaban, Rivaroxaban, Dabigatran and VKA in General Practice in the UK

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation

Stynes et al. /Poster

Aug. 28,14:00

Poster Area

Risk of Bleeding with Non-Vitamin K Antagonists and Phenprocoumon in Routine Care Patients with Non-Valvular Atrial Fibrillation

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation III

Hohnloser et al. /Poster

Aug. 28,14:00

Poster Area

Are Your Atrial Fibrillation (AF) Patients Protected from Ischaemic Stroke? Clinical Characteristics of AF Patients Eligible for Stroke Prevention but Remaining Untreated in UK Clinical Practice

Session: Poster Session 3: Anticoagulation in Atrial Fibrillation II

Ridha et al. /Poster

Aug. 28,14:00

Poster Area

Bleeding Risk for Non-Valvular AF Patients Prescribed Warfarin, or Standard Doses of Apixaban 5mg BID, Dabigatran 150mg BID or Rivaroxaban 20mg QD in Real-World Practice: Findings from EHR

Session: Are You Still Afraid about Bleeding Risk of Antithrombotic Therapy in Atrial Fibrillation?

Lip et al. /Oral, Advances in Science

Aug. 28,14:18

Minsk – Village 4

Demographic and Clinical Characteristics Associated with Initiation of Individual Oral Anticoagulants among Patients with Newly Diagnosed Venous Thromboembolism

Session: Poster Session 4: Thrombosis and Coagulation

Li et al. /Poster

Aug. 29,08:30

Poster Area

A Nationwide Register Study to Compare Bleeding Rates in Patients with Non-Valvular Atrial Fibrillation Prescribed Oral Anticoagulants

Session: Registries Atrial Fibrillation

Halvorsen et al. /Late-Breaker

Aug. 29,08:45

Raphael – The Hub

Costs of Major Adverse Outcomes in Patients with Incident Venous Thromboembolism in Clinical Practice in the United Kingdom

Session: Advances in Pulmonary Embolism

Cohen et al. /Poster

Aug. 29,16:03

Moderated Poster Station – Poster Area

Potential Impact of Apixaban on Hospital Resource Use in Patients with Venous Thromboembolism

Session: Antithrombotics in Daily Clinical Practice

Li et al. /Oral, Rapid Fire

Aug 30,17:24

Galileo – The Hub


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Related Entities

Twitter

Add Your Comment